This is a summary of the European public assessment report (EPAR) for Rixubis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rixubis. For practical information about using Rixubis, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Therapeutic Area (MeSH)
N/AATC Code
B02BD04
ATC Item
coagulation factor IX
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Nonacog gamma | N/A | Coagulation Factor IX (Recombinant) |
EMA Name
Rixubis
Medicine Name
Rixubis
Aliases
N/ANo risk management plan link.
